ClinicalTrials.gg
RecruitingNCT05755672On-CALLUpdated Jul 17, 2025

On-treatment Biomarkers in Metastatic Colorectal Cancer for Life

An observational study in Metastatic Colorectal Cancer, Chemotherapy Effect and Peritoneal Metastases, sponsored by Region Skane. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Region Skane · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Colorectal Neoplasms with a site in Sweden — 27 open to participants now, 38 under way, 10 of them phase 3. Colorectal Neoplasms · Sweden.

Planned enrollment
27th of 33
100 · median 242
Started
2023
with 7 others
Observational
33 of 124
9 open now
Primary completion
2026-12
later than 18 of 37 live
Registered
100th of 124
by date
Lead sponsor
5 of 124
Region Skane

Among the 124 studies in Colorectal Neoplasms with a site in Sweden, this one is the 27th largest by planned enrollment of the 33 observational ones that give a count, is one of 8 that started in 2023, is one of 33 observational ones, reaches primary completion later than 18 of the 37 other live ones, and was the 100th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

27 of the 124 studies in Colorectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Colorectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

By virtue of an increased strategic use of cytotoxic and biological agents, and more options for locoregional treatment, the survival of patients with metastatic colorectal cancer (mCRC) has improved considerably in the past decades. The personalized approach to systemic treatment is further aided by the use of complementary molecular biomarkers. However, the evolutionary dynamics of mCRC, a disease harnessed by multiple adaptive genetic alterations towards its final stages, poses a particular challenge to single-sample biomarker analyses and standardized linear treatment protocols. The aim of the On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study is to generate further knowledge on the evolutionary progression of mCRC during treatment, and to elucidate the mechanisms underlying the therapeutic failure still seen in a substantial number of patients.

The On-CALL study is a prospective, single-arm observational study. All patients diagnosed with synchronous mCRC treated with curative intent at Skåne University Hospital will be invited to participate. Clinical and histopathological data will be compiled at study entry. An individual tissue microarray block with samples from resected primary tumours and metastases representing the full extent of the tumour spread will be constructed for each patient. Blood samples will be drawn for biomarker analyses at multiple time points prior to, during and after systemic treatment. DNA sequencing of tumour tissue and circulating tumour DNA (ctDNA) will be performed to define the spatial clonal landscape in primary tumours and metastases, as well as over time.

Read the detailed description

The aim of the On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study is to generate further knowledge on the evolutionary progression of mCRC during treatment with curative intent, and to elucidate the mechanisms underlying the therapeutic failure still seen in a substantial number of patients.

The specific objectives are:

  • To comprehensively characterise the spatial intertumoural, intermetastatic and intrametastatic genetic heterogeneity
  • To delineate differences in the prevalence and type of genetic heterogeneity, as well as tumour evolvability, according to metastatic site
  • To examine the associations between spatial and temporal heterogeneity
  • To examine ctDNA quantity and quality as an early biomarker for response to neoadjuvant treatment
  • To examine ctDNA quantity and quality as an early biomarker for response to adjuvant treatment
  • To evaluate the relationship between phylogenetic patterns, i.e. the tumour evolvability, and survival in relation to different treatment modalities
  • To examine the heterogeneity of the tumour microenvironment in relation to the genetic heterogeneity and evolvability of the tumours
  • To examine circulating immune cells and inflammatory biomarkers, and their relationship with the genetic and microenvironmental heterogeneity of the tumours
  • To delineate parallel events at the transcriptomic and proteomic levels, with particular reference to their potential utility as clinically relevant surrogate biomarkers of genetic alterations underlying the evolvability of the tumours
03

Conditions studied

  • Metastatic Colorectal Cancer
  • Chemotherapy Effect
  • Peritoneal Metastases
  • Liver Metastasis Colon Cancer
  • Lung Metastases

Keywords

  • Metastatic colorectal cancer
  • Chemotherapy
  • Targeted therapy
  • Tumor heterogeneity
  • Tumor evolution
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients who are treated at the Skåne University Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of synchronous colorectal cancer, planned cancer treatment with curative intent at the Skåne University Hospital

Exclusion criteria

Exclusion Criteria:

  • Not accepting the study inclusion terms ( not obtained)
  • Age below or above the age limit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Synchronous mCRC patients

    Patients diagnosed with synchronous metastatic colorectal cancer with planned treatment with curative intent at Skåne University Hospital (Malmö and Lund), who have accepted the study invitation (agreeing to participation - informed consent)

    Drug: Chemotherapy · Procedure: Resection of the primary tumor · Procedure: Resection of tumour metastases · Procedure: Blood sampling during chemotherapy

Interventions

  • DrugChemotherapy

    Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines

  • ProcedureResection of the primary tumor

    Surgical resection of the primary tumour, according to the current clinical practice guidelines

    Also known as: Surgical resection of the primary tumour

  • ProcedureResection of tumour metastases

    Surgical resection of tumour metastases, according to the current clinical practice guidelines

    Also known as: Surgical resection of tumour metastases

  • ProcedureBlood sampling during chemotherapy

    Drawing of blood samples several times during patient visits for chemotherapy regimen

    Also known as: Drawing of blood samples during chemotherapy

06

What researchers measure

Primary outcomes

  1. Follow-up examination of tumour remission, progression or recurrence

    Radiological/clinical examination of tumour remission, progression or recurrence, and correlation of this clinical information with the available oncogenetic data from histological samples from the primary tumour and metastases, and from data from blood samples (ctDNA analysis) * Oncogenetic data will come from genomic profiling of tissue samples. This will be carried out by targeted deep sequencing (TDS), using a comprehensive panel covering cancer-related genes, in combination with genome wide SNP array for detection of copy number aberrations. * Data from blood samples will be extracted through quantification of ctDNA and monitoring of the temporal clonal dynamics (circulating cell free DNA will be extracted from plasma samples from all time points).

    Time frame: 10 years

Secondary outcomes

  1. Quality of life changes

    Patients will take quality-of-life surveys (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - version EORTC-QLQ-C30 and EORTC-QLQ-CR29) will assistance of medical professionals prior to and after neoadjuvant and/or adjuvant treatment. * These surveys are cancer-specific core questionnaires for use in relation to various cancers. * The questionnaire scales the items on a score of 1 (Not at all) to 4 (Very much), and 1 (Very poor) to 7 (Excellent). * Scoring result is 0 to 100; for functional and global quality of life scales, higher scores mean a better level of functioning, and for symptom-oriented scales, a higher score means worse/more severe symptoms. * Statistical analysis will be performed with the data from the questionnaires, and the evolution/changes of symptoms and subjective experiences of the patients will be quantified and correlated with the clinical findings.

    Time frame: 10 years

07

Study locations

2 of 2 sites recruiting
  • Department of Oncology, Hematology and Radiophysics, Skane University Hospital
    Lund, Skåne County 22241, Sweden
    Recruiting
  • Department of Oncology, Hematology and Radiophysics, Skane University Hospital
    Malmö, Skåne County 21428, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 45 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Mar 6, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2033
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05755672
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Mar 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Mar 2033 (estimated)
Last update
Jul 17, 2025

Study contacts

Danyil Kuznyecov, M.D.
Contact
danyil_szergejevics.kuznyecov@med.lu.se
+46 725972072
Christina Siesing, M.D. PhD.
Contact
christina.siesing@med.lu.se
+4646177841
Karin Jirström, M.D. PhD.
study director · Region Skane
Jakob Eberhard, M.D. PhD.
study chair · Region Skane

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion